Podcasts about OS

A Jacksonville Jaguars podcast. A little Xs and Os, a lot of vibes. Join our Discord Chat ► https://discord.gg/BJmXnbbUDonate $5/mo. to the cause of Dunn and Drew! It helps fight burnout! LOL ► Patreon.com/dunnanddrewMerch Store!! ► https://www.dunnanddrew.com/Join the Sports conversation in our Facebook Group ► https://www.facebook.com/groups/dunnanddrewHOW TO LISTEN TO DUNN AND DREW!!APPLE PODCASTS (Review and Rate us!) ► https://itunes.apple.com/us/podcast/dunn-and-drew/id1241016673?mt=2SPOTIFY ► https://open.spotify.com/show/1oGGXrtfCE1iaYmlJwXQod?si=LBFhTE5pSrq6aPVg8VLIIg••••••••••••••••••••••••••••••••••••••••­­­•••••••••••Keep up with us on social media!!TIK TOK: https://vm.tiktok.com/3KggT2/TWITTER: https://twitter.com/dunnanddrewINSTAGRAM: https://instagram.com/dunnanddrewFACEBOOK: https://www.facebook.com/dunnanddrew/BUSINESS INQUIRIES: dunnanddrew@gmail.com••••••••••••••••••••••••••••••••••••••••­­­•••••••••••Personal social media accountsTWITTER:DUNN: https://twitter.com/ericvdunnDREW: https://twitter.com/ndy_willisINSTAGRAM: DUNN: https://instagram.com/ericvdunn_DREW: https://instagram.com/ndywillis••••••••••••••••••••••••••••••••••••••••­­­•••••••••••PLEASE SUBSCRIBE! DUNN AND DREW BABY!!

New Open Indiana Release, Understanding Storage Performance, a Unix OS for the TI99, FreeBSD Tribal knowledge, and more... NOTES This episode of BSDNow is brought to you by Tarsnap (https://www.tarsnap.com/bsdnow) and the BSDNow Patreon (https://www.patreon.com/bsdnow) Headlines Signifier flotation devices (https://davidyat.es/2025/09/27/signifier-flotation-devices) Open Indiana Hipster Announcement (https://openindiana.org/announcements/openindiana-hipster-2025-10-announcement/) Understanding Storage Performance Metrics (https://klarasystems.com/articles/understanding-storage-performance-metrics?utm_source=BSD%20Now&utm_medium=Podcast) News Roundup UNIX99, a UNIX-like OS for the TI-99/4A (https://forums.atariage.com/topic/380883-unix99-a-unix-like-os-for-the-ti-994a) Making the veb(4) virtual Ethernet bridge VLAN aware (https://undeadly.org/cgi?action=article;sid=20251029114507) FreeBSD tribal knowledge: minor version upgrades (https://vulcanridr.mataroa.blog/blog/freebsd-tribal-knowledge-minor-version-upgrades) It's been 10 years since ZFS's 10th aniversary its integration into Solaris - A Reflection (https://blogs.oracle.com/oracle-systems/post/happy-10th-birthday-zfs) Tarsnap This weeks episode of BSDNow was sponsored by our friends at Tarsnap, the only secure online backup you can trust your data to. Even paranoids need backups. Feedback/Questions Send questions, comments, show ideas/topics, or stories you want mentioned on the show to feedback@bsdnow.tv (mailto:feedback@bsdnow.tv) Join us and other BSD Fans in our BSD Now Telegram channel (https://t.me/bsdnow)

PA hosts Xs and Os ahead of the matchup with the Packers and is joined by Vikings HC Kevin O'Connell!

PA hosts Xs and Os ahead of the matchup with the Packers and is joined by Vikings HC Kevin O'Connell!See omnystudio.com/listener for privacy information.

Dr. Linda Duska and Dr. Kathleen Moore discuss key studies in the evolving controversy over radical upfront surgery versus neoadjuvant chemotherapy in advanced ovarian cancer. TRANSCRIPT Dr. Linda Duska: Hello, and welcome to the ASCO Daily News Podcast. I am your guest host, Dr. Linda Duska. I am a professor of obstetrics and gynecology at the University of Virginia School of Medicine.  On today's episode, we will explore the management of advanced ovarian cancer, specifically with respect to a question that has really stirred some controversy over time, going all the way back more than 20 years: Should we be doing radical upfront surgery in advanced ovarian cancer, or should we be doing neoadjuvant chemotherapy? So, there was a lot of hype about the TRUST study, also called ENGOT ov33/AGO-OVAR OP7, a Phase 3 randomized study that compares upfront surgery with neoadjuvant chemotherapy followed by interval surgery. So, I want to talk about that study today. And joining me for the discussion is Dr. Kathleen Moore, a professor also of obstetrics and gynecology at the University of Oklahoma and the deputy director of the Stephenson Cancer Center, also at the University of Oklahoma Health Sciences.  Dr. Moore, it is so great to be speaking with you today. Thanks for doing this. Dr. Kathleen Moore: Yeah, it's fun to be here. This is going to be fun. Dr. Linda Duska: FYI for our listeners, both of our full disclosures are available in the transcript of this episode.  So let's just jump right in. We already alluded to the fact that the TRUST study addresses a question we have been grappling with in our field. Here's the thing, we have four prior randomized trials on this exact same topic. So, share with me why we needed another one and what maybe was different about this one? Dr. Kathleen Moore: That is, I think, the key question. So we have to level-set kind of our history. Let's start with, why is this even a question? Like, why are we even talking about this today? When we are taking care of a patient with newly diagnosed ovarian cancer, the aim of surgery in advanced ovarian cancer ideally is to prolong a patient's likelihood of disease-free survival, or if you want to use the term "remission," you can use the term "remission." And I think we can all agree that our objective is to improve overall survival in a way that also does not compromise her quality of life through surgical complications, which can have a big effect. The standard for many decades, certainly my entire career, which is now over 20 years, has been to pursue what we call primary cytoreductive surgery, meaning you get a diagnosis and we go right to the operating room with a goal of achieving what we call "no gross residual." That is very different – in the olden days, you would say "optimal" and get down to some predefined small amount of tumor. Now, the goal is you remove everything you can see.  The alternative strategy to that is neoadjuvant chemotherapy followed by interval cytoreductive surgery, and that has been the, quote-unquote, "safer" route because you chemically cytoreduce the cancer, and so, the resulting surgery, I will tell you, is not necessarily easy at all. It can still be very radical surgeries, but they tend to be less radical, less need for bowel resections, splenectomy, radical procedures, and in a short-term look, would be considered safer from a postoperative consideration. Dr. Linda Duska: Well, and also maybe more likely to be successful, right? Because there's less disease, maybe, theoretically. Dr. Kathleen Moore: More likely to be successful in getting to no gross residual. Dr. Linda Duska: Right. Yeah, exactly. Dr. Kathleen Moore: I agree with that. And so, so if the end game, regardless of timing, is you get to no gross residual and you help a patient and there's no difference in overall survival, then it's a no-brainer. We would not be having this conversation. But there remains a question around, while it may be more likely to get to no gross residual, it may be, and I think we can all agree, a less radical, safer surgery, do you lose survival in the long term by this approach? This has become an increasing concern because of the increase in rates of use of neoadjuvant, not only in this country, but abroad. And so, you mentioned the four prior studies. We will not be able to go through them completely. Dr. Linda Duska: Let's talk about the two modern ones, the two from 2020 because neither one of them showed a difference in overall survival, which I think we can agree is, at the end of the day, yes, PFS would be great, but OS is what we're looking for. Dr. Kathleen Moore: OS is definitely what we're looking for. I do think a marked improvement in PFS, like a real prolongation in disease-free survival, for me would be also enough. A modest improvement does not really cut it, but if you are really, really prolonging PFS, you should see that-  Dr. Linda Duska: -manifest in OS. Dr. Kathleen Moore: Yeah, yeah. Okay. So let's talk about the two modern ones. The older ones are EORTC and CHORUS, which I think we've talked about. The two more modern ones are SCORPION and JCOG0602. So, SCORPION was interesting. SCORPION was a very small study, though. So one could say it's underpowered. 170 patients. And they looked at only patients that were incredibly high risk. So, they had to have a Fagotti score, I believe, of over 9, but they were not looking at just low volume disease. Like, those patients were not enrolled in SCORPION. It was patients where you really were questioning, "Should I go to the OR or should I do neoadjuvant? Like, what's the better thing?" It is easy when it's low volume. You're like, "We're going." These were the patients who were like, "Hm, you know, what should I do?" High volume. Patients were young, about 55. The criticism of the older studies, there are many criticisms, but one of them is that, the criticism that is lobbied is that they did not really try. Whatever surgery you got, they did not really try with median operative times of 180 minutes for primary cytoreduction, 120 for neoadjuvant. Like, you and I both know, if you're in a big primary debulking, you're there all day. It's 6 hours. Dr. Linda Duska: Right, and there was no quality control for those studies, either. Dr. Kathleen Moore: No quality control. So, SCORPION, they went 451-minute median for surgery. Like, they really went for it versus four hours and then 253 for the interval, 4 hours. They really went for it on both arms. Complete gross resection was achieved in 50% of the primary cytoreduced. So even though they went for it with these very long surgeries, they only got to the goal half the time. It was almost 80% in the interval group. So they were more successful there. And there was absolutely no difference in PFS or OS. They were right about 15 months PFS, right about 40 months OS.  JCOG0602, of course, done in Japan, a big study, 300 patients, a little bit older population. Surprisingly more stage IV disease in this study than were in SCORPION. SCORPION did not have a lot of stage IV, despite being very bulky tumors. So a third of patients were stage IV. They also had relatively shorter operative times, I would say, 240 minutes for primary, 302 for interval. So still kind of short. Complete gross resection was not achieved very often. 30% of primary cytoreduction. That is not acceptable. Dr. Linda Duska: Well, so let's talk about TRUST. What was different about TRUST? Why was this an important study for us to see? Dr. Kathleen Moore: So the criticism of all of these, and I am not trying to throw shade at anyone, but the criticism of all of these is if you are putting surgery to the test, you are putting the surgeon to the test. And you are assuming that all surgeons are trained equally and are willing to do what it takes to get someone to no gross residual. Dr. Linda Duska: And are in a center that can support the post-op care for those patients. Dr. Kathleen Moore: Which can be ICU care, prolonged time. Absolutely. So when you just open these broadly, you're assuming everyone has the surgical skills and is comfortable doing that and has backup. Everybody has an ICU. Everyone has a blood bank, and you are willing to do that. And that assumption could be wrong. And so what TRUST said is, "Okay, we are only going to open this at centers that have shown they can achieve a certain level of primary cytoreduction to no gross residual disease." And so there was quality criteria. It was based on – it was mostly a European study – so ESGO criteria were used to only allow certified centers to participate. They had to have a surgical volume of over 36 cytoreductive surgeries per year. So you could not be a low volume surgeon. Your complete resection rates that were reported had to be greater than 50% in the upfront setting. I told you on the JCOG, it was 30%. Dr. Linda Duska: Right. So these were the best of the best. This was the best possible surgical situation you could put these patients in, right? Dr. Kathleen Moore: Absolutely. And you support all the things so you could mitigate postoperative complications as well. Dr. Linda Duska: So we are asking the question now again in the ideal situation, right? Dr. Kathleen Moore: Right. Dr. Linda Duska: Which, we can talk about, may or may not be generalizable to real life, but that's a separate issue because we certainly don't have those conditions everywhere where people get cared for with ovarian cancer. But how would you interpret the results of this study? Did it show us anything different? Dr. Kathleen Moore: I am going to say how we should interpret it and then what I am thinking about. It is a negative study. It was designed to show improvement in overall survival in these ideal settings in patients with FIGO stage IIIB and C, they excluded A, these low volume tumors that should absolutely be getting surgery. So FIGO stage IIIB and C and IVA and B that were fit enough to undergo radical surgery randomized to primary cytoreduction or neoadjuvant with interval, and were all given the correct chemo. Dr. Linda Duska: And they were allowed bevacizumab and PARP, also. They could have bevacizumab and PARP. Dr. Kathleen Moore: They were allowed bevacizumab and PARP. Not many of them got PARP, but it was distributed equally, so that would not be a confounder. And so that was important. Overall survival is the endpoint. It was a big study. You know, it was almost 600 patients. So appropriately powered. So let's look at what they reported. When they looked at the patients who were enrolled, this is a large study, almost 600 patients, 345 in the primary cytoreductive arm and 343 in the neoadjuvant arm. Complete resection in these patients was 70% in the primary cytoreductive arm and 85% in the neoadjuvant arm. So in both arms, it was very high. So your selection of site and surgeon worked. You got people to their optimal outcome. So that is very different than any other study that has been reported to date. But what we saw when we looked at overall survival was no statistical difference. The median was, and I know we do not like to talk about medians, but the median in the primary cytoreductive arm was 54 months versus 48 months in the neoadjuvant arm with a hazard ratio of 0.89 and, of course, the confidence interval crossed one. So this is not statistically significant. And that was the primary endpoint. Dr. Linda Duska: I know you are getting to this. They did look at PFS, and that was statistically significant, but to your point about what are we looking for for a reasonable PFS difference? It was about two months difference. When I think about this study, and I know you are coming to this, what I thought was most interesting about this trial, besides the fact that the OS, the primary endpoint was negative, was the subgroup analyses that they did. And, of course, these are hypothesis-generating only. But if you look at, for example, specifically only the stage III group, that group did seem to potentially, again, hypothesis generating, but they did seem to benefit from upfront surgery.  And then one other thing that I want to touch on before we run out of time is, do we think it matters if the patient is BRCA germline positive? Do we think it matters if there is something in particular about that patient from a biomarker standpoint that is different? I am hopeful that more data will be coming out of this study that will help inform this. Of course, unpowered, hypothesis-generating only, but it's just really interesting. What do you think of their subset analysis? Dr. Kathleen Moore: Yeah, I think the subsets are what we are going to be talking about, but we have to emphasize that this was a negative trial as designed. Dr. Linda Duska: Absolutely. Yes. Dr. Kathleen Moore: So we cannot be apologists and be like, "But this or that." It was a negative trial as designed. Now, I am a human and a clinician, and I want what is best for my patients. So I am going to, like, go down the path of subset analyses. So if you look at the stage III tumors that got complete cytoreduction, which was 70% of the cases, your PFS was almost 28 months versus 21.8 months. Dr. Linda Duska: Yes, it becomes more significant. Dr. Kathleen Moore: Yeah, that hazard ratio is 0.69. Again, it is a subset. So even though the P value here is statistically significant, it actually should not have a P value because it is an exploratory analysis. So we have to be very careful. But the hazard ratio is 0.69. So the hypothesis is in this setting, if you're stage III and you go for it and you get someone to no gross residual versus an interval cytoreduction, you could potentially have a 31% reduction in the rate of progression for that patient who got primary cytoreduction. And you see a similar trend in the stage III patients, if you look at overall survival, although the post-progression survival is so long, it's a little bit narrow of a margin.  But I do think there are some nuggets here that, one of our colleagues who is really one of the experts in surgical studies, Dr. Mario Leitao, posted this on X, and I think it really resonated after this because we were all saying, "But what about the subsets?" He is like, "It's a negative study." But at the end of the day, you are going to sit with your patient. The patient should be seen by a GYN oncologist or surgical oncologist with specialty in cytoreduction and a medical oncologist, you know, if that person does not give chemo, and the decision should be made about what to do for that individual patient in that setting. Dr. Linda Duska: Agreed. And along those lines, if you look carefully at their data, the patients who had an upfront cytoreduction had almost twice the risk of having a stoma than the patients who had an interval cytoreduction. And they also had a higher risk of needing to have a bowel resection. The numbers were small, but still, when you look at the surgical complications, as you've already said, they're higher in the upfront group than they are in the interval group. That needs to be taken into account as well when counseling a patient, right? When you have a patient in front of you who says to you, "Dr. Moore, you can take out whatever you want, but whatever you do, don't make me a bag." As long as the patient understands what that means and what they're asking us to do, I think that we need to think about that. Dr. Kathleen Moore: I think that is a great point. And I have definitely seen in our practice, patients who say, "I absolutely would not want an ostomy. It's a nonstarter for me." And we do make different decisions. And you have to just say, "That's the decision we've made," and you kind of move on, and you can't look back and say, "Well, I wish I would have, could have, should have done something else." That is what the patient wants. Ultimately, that patient, her family, autonomous beings, they need to be fully counseled, and you need to counsel that patient as to the site that you are in, her volume of disease, and what you think you can achieve. In my opinion, a patient with stage III cancer who you have the site and the capabilities to get to no gross residual should go to the OR first. That is what I believe. I do not anymore think that for stage IV. I think that this is pretty convincing to me that that is probably a harmful thing. However, I want you to react to this. I think I am going to be a little unpopular in saying this, but for me, one of the biggest take-homes from TRUST was that whether or not, and we can talk about the subsets and the stage III looked better, and I think it did, but both groups did really well. Like, really well. And these were patients with large volume disease. This was not cherry-picked small volume stage IIIs that you could have done an optimal just by doing a hysterectomy. You know, these were patients that needed radical surgery. And both did well. And so what it speaks to me is that anytime you are going to operate on someone with ovary, whether it be frontline, whether it be a primary or interval, you need a high-volume surgeon. That is what I think this means to me. Like, I would want high volume surgeon at a center that could do these surgeries, getting that patient, my family member, me, to no gross residual. That is important. And you and I are both in training centers. I think we ought to take a really strong look at, are we preparing people to do the surgeries that are necessary to get someone to no gross residual 70% and 85% of the time? Dr. Linda Duska: We are going to run out of time, but I want to address that and ask you a provocative question. So, I completely agree with what you said, that surgery is important. But I also think one of the reasons these patients in this study did so well is because all of the incredible new therapies that we have for patients. Because OS is not just about surgery. It is about surgery, but it is also about all of the amazing new therapies we have that you and others have helped us to get through clinical research. And so, how much of that do you think, like, for example, if you look at the PFS and OS rates from CHORUS and EORTC, I get it that they're, that they're not the same. It's different patients, different populations, can't do cross-trial comparisons. But the OS, as you said, in this study was 54 months and 48 months, which is, compared to 2010, we're doing much, much better. It is not just the surgery, it is also all the amazing treatment options we have for these patients, including PARP, including MIRV, including lots of other new therapies. How do you fit that into thinking about all of this? Dr. Kathleen Moore: I do think we are seeing, and we know this just from epidemiologic data that the prevalence of ovarian cancer in many of the countries where the study was done is increasing, despite a decrease in incidence. And why is that? Because people are living longer. Dr. Linda Duska: People are living longer, yeah. Dr. Kathleen Moore: Which is phenomenal. That is what we want. And we do have, I think, better supportive care now. PARP inhibitors in the frontline, which not many of these patients had. Now some of them, this is mainly in Europe, will have gotten them in the first maintenance setting, and I do think that impacts outcome. We do not have that data yet, you know, to kind of see what, I would be really interested to see. We do not do this well because in ovarian cancer, post-progression survival can be so long, we do not do well of tracking what people get when they come off a clinical trial to see how that could impact – you know, how many of them got another surgery? How many of them got a PARP? I think this group probably missed the ADC wave for the most part, because this, mirvetuximab is just very recently available in Europe. Dr. Linda Duska: Unless they were on trial. Dr. Kathleen Moore: Unless they were on trial. But I mean, I think we will have to see. 600 patients, I would bet a lot of them missed the ADC wave. So, I do not know that we can say we know what drove these phenomenal – these are some of the best curves we've seen outside of BRCA. And then coming back to your point about the BRCA population here, that is a really critical question that I do not know that we're ever going to answer. There have been hypotheses around a tumor that is driven by BRCA, if you surgically cytoreduced it, and then chemically cytoreduced it with chemo, and so you're starting PARP with nothing visible and likely still homogeneous clones. Is that the group we cured? And then if you give chemo first before surgery, it allows more rapid development of heterogeneity and more clonal evolution that those are patients who are less likely to be cured, even if they do get cytoreduced to nothing at interval with use of PARP inhibitor in the front line. That is a question that many have brought up as something we would like to understand better. Like, if you are BRCA, should you always just go for it or not? I do not know that we're ever going to really get to that. We are trying to look at some of the other studies and just see if you got neoadjuvant and you had BRCA, was anyone cured? I think that is a question on SOLO1 I would like to know the answer to, and I don't yet, that may help us get to that. But that's sort of something we do think about. You should have a fair number of them in TRUST. It wasn't a stratification factor, as I remember. Dr. Linda Duska: No, it wasn't. They stratified by center, age, and ECOG status Dr. Kathleen Moore: So you would hope with randomization that you would have an equal number in each arm. And they may be able to pull that out and do a very exploratory look. But I would be interested to see just completely hypothesis-generating what this looks like for the patients with BRCA, and I hope that they will present that. I know they're busy at work. They have translational work. They have a lot pending with TRUST. It's an incredibly rich resource that I think is going to teach us a lot, and I am excited to see what they do next. Dr. Linda Duska: So, outside of TRUST, we are out of time. I just want to give you a moment if there were any other messages that you want to share with our listeners before we wrap up. Dr. Kathleen Moore: It's an exciting time to be in GYN oncology. For so long, it was just chemo, and then the PARP inhibitors nudged us along quite a bit. We did move more patients, I believe, to the cure fraction. When we ultimately see OS, I think we'll be able to say that definitively, and that is exciting. But, you know, that is the minority of our patients. And while HRD positive benefits tremendously from PARP, I am not as sure we've moved as many to the cure fraction. Time will tell. But 50% of our patients have these tumors that are less HRD. They have a worse prognosis. I think we can say that and recur more quickly. And so the advent of these antibody-drug conjugates, and we could name 20 of them in development in GYN right now, targeting tumor-associated antigens because we're not really driven by mutations other than BRCA. We do not have a lot of things to come after. We're not lung cancer. We are not breast cancer. But we do have a lot of proteins on the surface of our cancers, and we are finally able to leverage that with some very active regimens. And we're in the early phases, I would say, of really understanding how best to use those, how best to position them, and which one to select for whom in a setting where there is going to be obvious overlap of the targets. So we're going to be really working this problem. It is a good problem. A lot of drugs that work pretty well. How do you individualize for a patient, the patient in front of you with three different markers? How do you optimize it? Where do you put them to really prolong survival? And then we finally have cell surface. We saw at ASCO, CDK2 come into play here for the first time, we've got a cell cycle inhibitor. We've been working on WEE1 and ATR for a long time. CDK2s may hit. Response rates were respectable in a resistant population that was cyclin E overexpressing. We've been working on that biomarker for a long time with a toxicity profile that was surprisingly clean, which I like to see for our patients. So that is a different platform. I think we have got bispecifics on the rise. So there is a pipeline of things behind the ADCs, which is important because we need more than one thing, that makes me feel like in the future, I am probably not going to be using doxil ever for platinum-resistant disease. So, I am going to be excited to retire some of those things. We will say, "Remember when we used to use doxil for platinum-resistant disease?" Dr. Linda Duska: I will be retired by then, but thanks for that thought. Dr. Kathleen Moore: I will remind you. Dr. Linda Duska: You are right. It is such an incredibly exciting time to be taking care of ovarian cancer patients with all the opportunities.  And I want to thank you for sharing your valuable insights with us on this podcast today and for your great work to advance care for patients with GYN cancers. Dr. Kathleen Moore: Likewise. Thanks for having me. Dr. Linda Duska: And thank you to our listeners for your time today. You will find links to the TRUST study and other studies discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Linda Duska  @Lduska Dr. Kathleen Moore Follow ASCO on social media:     @ASCO on X (formerly Twitter) ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures of Potential Conflicts of Interest:    Dr. Linda Duska:   Consulting or Advisory Role: Regeneron, Inovio Pharmaceuticals, Merck, Ellipses Pharma  Research Funding (Inst.): GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Aeterna Zentaris, Novartis, Abbvie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Ludwig Institute for Cancer Research, Leap Therapeutics  Patents, Royalties, Other Intellectual Property: UptToDate, Editor, British Journal of Ob/Gyn  Dr. Kathleen Moore: Leadership: GOG Partners, NRG Ovarian Committee Chair Honoraria: Astellas Medivation, Clearity Foundation, IDEOlogy Health, Medscape, Great Debates and Updates, OncLive/MJH Life Sciences, MD Outlook, Curio Science, Plexus, University of Florida, University of Arkansas for Medical Sciences, Congress Chanel, BIOPHARM, CEA/CCO, Physician Education Resource (PER), Research to Practice, Med Learning Group, Peerview, Peerview, PeerVoice, CME Outfitters, Virtual Incision Consulting/Advisory Role: Genentech/Roche, Immunogen, AstraZeneca, Merck, Eisai, Verastem/Pharmacyclics, AADi, Caris Life Sciences, Iovance Biotherapeutics, Janssen Oncology, Regeneron, zentalis, Daiichi Sankyo Europe GmbH, BioNTech SE, Immunocore, Seagen, Takeda Science Foundation, Zymeworks, Profound Bio, ADC Therapeutics, Third Arc, Loxo/Lilly, Bristol Myers Squibb Foundation, Tango Therapeutics, Abbvie, T Knife, F Hoffman La Roche, Tubulis GmbH, Clovis Oncology, Kivu, Genmab/Seagen, Kivu, Genmab/Seagen, Whitehawk, OnCusp Therapeutics, Natera, BeiGene, Karyopharm Therapeutics, Day One Biopharmaceuticals, Debiopharm Group, Foundation Medicine, Novocure Research Funding (Inst.): Mersana, GSK/Tesaro, Duality Biologics, Mersana, GSK/Tesaro, Duality Biologics, Merck, Regeneron, Verasatem, AstraZeneca, Immunogen, Daiichi Sankyo/Lilly, Immunocore, Torl Biotherapeutics, Allarity Therapeutics, IDEAYA Biosciences, Zymeworks, Schrodinger Other Relationship (Inst.): GOG Partners

Imagina guerreros que luchaban desnudos, aullaban como lobos, mordían sus escudos y atacaban con una ira tan ciega que podían destrozar a amigos y enemigos por igual. Los berserkers vikingos fueron las tropas de élite más temidas de la Edad Media, pero ¿qué se escondía detrás de su comportamiento enloquecido? Un etnobotánico esloveno ha desvelado el secreto: un cóctel letal de hongos alucinógenos y beleño negro, la misma hierba que usaban las brujas medievales. Una pócima que provocaba alucinaciones, fuerza sobrehumana y una rabia homicida incontrolable. Hoy descubrimos la química detrás del mito, el ritual chamánico que los convertía en hombres lobo y por qué terminaron siendo declarados ilegales por sus propios compatriotas. Bienvenidos a DÍAS EXTRAÑOS. Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

JUEVES 20 DE NOVIEMBRE DE 2025 TU DOSIS DIARIA DE ESPERANZA "Cuando, pues, os reunís vosotros, esto no es comer la cena del Señor. Porque al comer, cada uno se adelanta a tomar su propia cena; y uno tiene hambre, y otro se embriaga. Pues qué, ¿no tenéis casas en que comáis y bebáis? ¿O menospreciáis la iglesia de Dios, y avergonzáis a los que no tienen nada? ¿Qué os diré? ¿Os alabaré? En esto no os alabo." (1Corintios 11:20-22) Los corintios se creían tan superiores que hicieron de la Cena del Señor y la que la antecedía, un festín carnal. La gente pobre no era tenida en cuenta; cuando llegaban ya no les quedaba nada. (vs22). Para muchos hoy las celebraciones cristianas carecen de valor; las ven como costumbres sin sentido ante tanta sabiduría humana y adelantos científicos. Otros asisten por costumbre. Lo cierto es que nos perdemos de entrar a lo sobrenatural ante un recordatorio que nos hace disfrutar de la espiritualidad que la enriquece. Revisemos nuestra vida. ¿Le damos a la Santa Cena el valor inmenso que le da el Señor? El apóstol nos exhorta: Pruébese cada uno a sí mismo. (Gina Sánchez) ....... www.facebook.com/PastoresRobertoyYamiley Apple: https://podcasts.apple.com/us/podcast/tu-dosis-diaria-de-esperanza-new-hope-en-espa%C3%B1ol/id1503374265 Spotify: https://open.spotify.com/show/0dC8BmYXC77tIaReY6JI6y?si=adf3392aa15e45c7 iHeart Radio: https://www.iheart.com/podcast/263-tu-dosis-diaria-de-esperan-211298038/ ....... Pastores Roberto y Yamiley, De Dios Para Ti Hoy - New Hope en Español , Brandon, FL (813) 689-4161

Confira os destaques do Jornal da Manhã desta quinta-feira (20): O Tribunal de Contas do Rio de Janeiro quer saber quais movimentações financeiras do estado têm relação com o Banco Master. A decisão foi tomada na última quarta-feira (19), um dia após o escândalo que sacudiu o sistema financeiro brasileiro. Reportagem: Rodrigo Viga. A partir da próxima sexta-feira (21), novos usuários da Previdência Social e requerentes do Benefício de Prestação Continuada (BPC) terão que realizar o cadastro de biometria para a concessão do auxílio. O BPC garante o pagamento de um salário mínimo mensal a idosos com 65 anos ou mais e a pessoas com deficiência de baixa renda. A medida visa aumentar a segurança e evitar fraudes. Reportagem: Matheus Dias. Após sofrer uma derrota na Câmara dos Deputados, o Governo Federal articula estratégias para reverter pontos do PL Antifacção no Senado. O projeto chega à Casa Alta sob forte expectativa de alterações. Na última terça-feira (18), a Câmara dos Deputados contrariou o Planalto e aprovou o parecer de Guilherme Derrite (Progressistas), secretário licenciado de Segurança Pública de São Paulo. Reportagem: Victoria Abel. O deputado federal Eduardo Bolsonaro (PL) foi incluído na dívida ativa da União após ter faltas injustificadas na Câmara dos Deputados. O deputado deve cerca de R$ 14 mil por quatro faltas em março deste ano, quando se mudou para os Estados Unidos, mas ainda não tinha formalizado o afastamento temporário do mandato. Reportagem: Igor Damasceno. Os presidentes do Senado, Câmara e STF se reuniram em Brasília na última quarta-feira (19). Entre os assuntos discutidos, Hugo Motta (Republicanos), Davi Alcolumbre (União Brasil) e Edson Fachin conversaram sobre a criação de um Marco Legal de Combate ao Crime Organizado, além de reajuste de salário e criação de novos cargos. As posições recentes do vice-prefeito de São Paulo, Mello Araújo (PL), cobrando mérito pelo fim da concentração de usuários de drogas na chamada Cracolândia, na capital paulista, não foram bem avaliadas pelos aliados do prefeito da cidade, Ricardo Nunes (MDB), e do governador Tarcísio de Freitas (Republicanos). A avaliação interna é de que Mello Araújo age de forma isolada, enquanto as gestões municipal e estadual trabalham em conjunto. Para discutir o assunto, a Jovem Pan News recebe o deputado federal Cezinha de Madureira (PSD-SP). Reportagem: Beatriz Manfredini. O deputado federal Alexandre Ramagem (PL-RJ) foi visto em Miami, nos Estados Unidos, segundo um jornalista do portal PlatôBR. Ramagem, que foi condenado a 16 anos de prisão por envolvimento na tentativa de golpe de Estado, está proibido de deixar o Brasil por determinação do STF. Embora a defesa tenha recorrido da sentença, a viagem infringe as medidas cautelares impostas e eleva o alerta das autoridades para um alto risco de fuga. Reportagem: Igor Damasceno. O chanceler da Alemanha, Friedrich Merz, afirmou que não vai pedir desculpas pelos comentários feitos em relação à cidade de Belém. Além disso, o porta-voz do governo da Alemanha, Stefan Kornelius, disse que a frase do mandatário sobre a COP30 está sendo apresentada de forma incriminatória. Reportagem: Luca Bassani. O presidente dos Estados Unidos, Donald Trump, sancionou a lei que torna públicos todos os arquivos da investigação do caso Epstein. O Congresso norte-americano já tinha aprovado o projeto, e havia uma grande expectativa sobre se o presidente seria favorável. O magnata cometeu suicídio na prisão em 2019, antes de ser julgado por liderar uma rede de abuso sexual de menores. Reportagem: Eliseu Caetano. Essas e outras notícias você acompanha no Jornal da Manhã. Learn more about your ad choices. Visit megaphone.fm/adchoices

Clima de celebração hoje. Os olhos do mundo estão no Pará — COP acontecendo, Círio ainda quente no coração — e a nossa convidada é um dos nomes que transformaram essa energia em linguagem. Multiartista amazônica que botou o tecnobrega no centro do pop, ela abriu caminho para uma geração inteira: 27 anos de estrada, a primeira paraense no Palco Mundo do Rock in Rio, Latin Grammy e, com sua obra reconhecida como Patrimônio Cultural e Imaterial do Estado do Pará. Mas título nenhum explica sozinho o que acontece quando ela chega: a rua vira palco, a aparelhagem vira cinema de som e luz, o sagrado dança com o profano. Do Jurunas pro mundo, a Gaby sempre fez da pista uma tese — e agora dobra a aposta com Rock Doido, um álbum-filme pensado como set contínuo, plano-sequência, cidade em movimento. É festa, é manifesto, é técnica, é afeto. Hoje a conversa é pra honrar essa trajetória e olhar pra frente pra uma Amazônia que não é cenário, é sujeito, pra nos lambuzar de uma fartura cultural que exige seu espaço na identidade brasileira. Gaby Amarantos, bem-vinda ao Mamilos! Anuncie no Mamilos ou contrate a consultoria Milos: mamilos@mamilos.me Saiba mais em Mamilos.me Este programa é um oferecimento TotalPass e Insider.

Veja também em youtube.com/@45_graus Zita Seabra nasceu em 1949. Foi deputada à Assembleia da República de 1975 a 1988, coordenou o Secretariado Nacional para o Audiovisual em 1993, ano em que assumiu a presidência do Instituto Português de Cinema. De 1994 a 1995, foi presidente do Instituto Português da Arte Cinematográfica e Audiovisual. É editora e autora de Foi Assim (Alêtheia, 2007), onde partilha as suas memórias desde a infância até ao momento de ruptura com o Partido Comunista Português, altura em que publicou O Nome das Coisas (Publicações Europa-América, 1988). Desde 2005, dirige a Alêtheia Editores, da qual é fundadora, assim como a Várzea da Rainha Impressores. Há longos anos no meio editorial, foi editora da Quetzal e também administradora e directora editorial da Bertrand Editora. _______________ Índice: (0:00) Introdução (4:32) O que atrai um(a) jovem no comunismo? | Comunismo vs maoismo vs trotskismo | Os totalitarismos e os perigos do intelectualismo excessivo (26:54) Quem militava naqueles partidos sabia o que se passava na URSS e na China maoista? | Porque o comunismo deu sempre em totalitarismo? (35:42) O que a fez a primeira vez duvidar, e como saiu do PCP? | Mikhail SuslovSee omnystudio.com/listener for privacy information.

Send us a text

No “Estadão Analisa” desta quarta-feira, 19, Carlos Andreazza comenta sobre derrota do governo no plenário da Câmara com a aprovação do texto de Guilherme Derrite (PP-SP). O governo Lula ainda vê um “caos jurídico” com o PL e já articula salvar no Senado o projeto de lei antifacção elaborado pelo Ministério da Justiça. O sexto relatório elaborado por Derrite em menos de duas semanas foi aprovado por 370 a 110 votos. Os primeiros pareceres foram alvo de críticas, em meio a uma insatisfação generalizada com pontos controversos. O secretário de Assuntos Legislativos do ministério, Marivaldo Pereira, responsável pela articulação da pasta com o Congresso, diz que quase nada do projeto do governo sobrou no relatório aprovado em plenário. A avaliação do Planalto é que o projeto, do jeito que está, deve criar um “caos jurídico” a partir do conflito entre diferentes legislações sobre o mesmo tema, o que deve favorecer os réus. Assine por R$1,90/mês e tenha acesso ilimitado ao conteúdo do Estadão.Acesse: https://bit.ly/oferta-estadao O 'Estadão Analisa' é transmitido ao vivo de segunda a sexta-feira, às 7h, no Youtube e redes sociais do Estadão. Também disponível no agregador de podcasts de sua preferência. Apresentação: Carlos AndreazzaEdição/Produção: Jefferson PerlebergCoordenação: Leonardo Cruz e Everton OliveiraSee omnystudio.com/listener for privacy information.

Os parlamentares vão verificar o impacto dessas obras sobre a qualidade de vida dos moradores, nesta 2ª f (24/11), entre os bairros Nova Gameleira e Nova Cintra.

Apple has introduced Digital IDs as a new feature in their latest OS. This is not just an Apple feature, but a rollout that is integrated with TSA and over 200 airports. Digital IDs are not popular; they are also the critical piece to that links a person's biometrics and life profiles to the digital currencies. The digital currencies are also moving forward. The elites are keeping people busy looking different places as they sell the "solution" for a better future to allow for a peaceful rollout of the new slave system. Don't get complacent.  #BardsFM #Digital_IDs #BeastSystem Bards Nation Health Store: www.bardsnationhealth.com EnviroKlenz Air Purification, promo code BARDS to save 10%:www.enviroklenz.com EMPShield protect your vehicles and home. Promo code BARDS: Click here MYPillow promo code: BARDS >> Go to https://www.mypillow.com/bards and use the promo code BARDS or... Call 1-800-975-2939.  White Oak Pastures Grassfed Meats, Get $20 off any order $150 or more. Promo Code BARDS: www.whiteoakpastures.com/BARDS BardsFM CAP, Celebrating 50 Million Downloads: https://ambitiousfaith.net Morning Intro Music Provided by Brian Kahanek: www.briankahanek.com Windblown Media 20% Discount with promo code BARDS: windblownmedia.com Founders Bible 20% discount code: BARDS >>> TheFoundersBible.com Mission Darkness Faraday Bags and RF Shielding. Promo code BARDS: Click here EMF Solutions to keep your home safe: https://www.emfsol.com/?aff=bards Treadlite Broadforks...best garden tool EVER. Promo code BARDS: TreadliteBroadforks.com No Knot Today Natural Skin Products: NoKnotToday.com Health, Nutrition and Detox Consulting: HealthIsLocal.com Destination Real Food Book on Amazon: click here Images In Bloom Soaps and Things: ImagesInBloom.com Angeline Design: AngelineDesign.com DONATE: Click here Mailing Address: Xpedition Cafe, LLC Attn. Scott Kesterson 591 E Central Ave, #740 Sutherlin, OR  97479

With the help of Josh Hardy, Co-Founder and CTO of Orb, we introduce Orb.  Orb is a suite app for OS, Android, macOS, Windows, Linux that is a new way to look at your internet connectivity.  Josh gives us a little background on why and how Orb was created,  He then goes into more detail... Read more »

Leah Price, VP of the Tinman AI platform at Better.com, joins OPTO Sessions to unpack the company's pivot to a full-stack GenAI mortgage OS and Betsy, the chat- and voice-based assistant embedded across the experience - delivering up to 75% faster cycle times, 45% lower fulfilment costs, and 10× volume, plus a first look at a pre-release avatar advisor.-----The content in this podcast is for informational purposes only. Opto Markets LLC does not recommend any specific securities or investment strategies. Investing involves risk & investments may lose value, including the loss of principal. Past performance does not guarantee future results. Investors should consider their investment objectives and risks carefully before investing. The information provided is not an endorsement of this product and is for information and/or educational purposes only.

Durante este programa, Núbia, de 24 anos de idade, disse que namora há oito anos com um rapaz da mesma idade que ela. A aluna paga a faculdade e o casal está construindo a casa deles; por isso, não haverá festa de casamento, já que eles precisam comprar os móveis. Núbia confessou que, para ela, está muito difícil essa situação de não ter uma festa. O casal blindado falou amplamente sobre esse assunto. Convite especialNesta quinta-feira (20), participe da Hora dos Solteiros, a partir das 18h, na Esplanada do Templo de Salomão, no Brás, em São Paulo. Se você é solteiro, aproveite essa oportunidade para investir de forma significativa na sua vida amorosa.Em seguida, às 20h, esteja presente também na palestra da Terapia do Amor. Para consultar outros locais e endereços, acesse terapiadoamor.tv ou ligue para (11) 3573-3535.Inclusive, não perca a série de palestras “Cortando as Raízes Ruins”, uma sequência de encontros destinados a ajudar casais e solteiros a reconhecerem as raízes mais profundas de seus desafios amorosos e a reconstruírem sua relação com o amor.Pegando antipatia Em seguida, Gleice pediu a ajuda dos professores. Ela se casou há seis meses e o marido vive nas redes sociais e WhatsApp. Antes de se casarem, ele não tinha Facebook, ativou após o casamento. Os dois não têm diálogo, não a dá atenção e estão vivendo como dois amigos dentro de casa. Inclusive, Gleice comentou que está tomando antipatia pela cara dele e pensando em se separar. A aluna perguntou o que fazer. Bem-vindos à Escola do Amor Responde, confrontando os mitos e a desinformação nos relacionamentos. Onde casais e solteiros aprendem o Amor Inteligente. Renato e Cristiane Cardoso, apresentadores da Escola do Amor, na Record TV, e autores de Casamento Blindado e Namoro Blindado, tiram dúvidas e respondem perguntas dos alunos. Participe pelo site EscoladoAmorResponde.com. Ouça todos os podcasts no iTunes: rna.to/EdARiTunes

ROFL! This week the boys celebrate Gavin's birthday with some of his favorite stories of the week, including LeBron James being random on Twitter, a new bagpiper world record, Funk Pops, Dwayne 'The Rock' Johnson, and a special appearance from Gavin's brother Sean! Plus the guys bid farewell to the Penny, face-off in some Star Wars trivia, and share what they've been listening to in the past week. Enjoy! Want to stay up to date with the podcast? Give us a follow on our social media platforms, and check out the video version of this show on YouTube in the links below! Instagram: https://www.instagram.com/ittakesallkindspodcast/ Twitter: https://twitter.com/ITAKPodcast YouTube: https://youtube.com/playlist?list=PLSQ1H-tYJrxroyz82ygvJoI9splHke-Ez 00:00 Intro 00:53 Happy Birthday Gavin! 03:48 Government shutdown is over 11:43 Gavin's surprise! 18:23 RIP to the Penny 24:24 LeBron James Is SO Random 30:55 Bagpiper world record 43:52 What's your birthday Funko Pop? 52:13 Dwayne 'The Rock' Johnson on Os*ma's d*ath 56:18 Sean goes to the shooting range 01:05:55 Star Wars Trivia Showdown 01:12:09 Whatcha Listening To? 01:15:59 Outro

durée : 00:45:40 - La 20e heure - par : Eva Bester - Le philosophe de formation Aurélien Bellanger, tout à la fois écrivain, essayiste et chroniqueur radio, vient nous présenter son livre "Grottes, baleine, révolution" publié au Seuil et sa correspondance avec l'écrivaine sociologue Kaoutar Harchi, "Sans parler des blessé·es" chez La Déferlante. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

Os pequeninos sabem o que é um espião, a Inês rebenta um pneu e a Joana recebe notícias sobre o seu carro, mas não percebe nada de mecânica.

Abrimos la Taberna para charlar sobre la actualidad y bueno... más cosas. Con Eneko Carrillo, Cristian Miconi, Javi Aguilar y Albert Rivera.... y la estrella invitada Mikel Ilundain. Os recordamos que podéis veniros a la Quedada ACDP el próximo 29 de noviembre. Toda la info en la pestaña de comunidad. O escribiendo a contacto@alacoladelpeloton.es Identidad CLAS on Tour 2025 Nuevas fechas confirmadas: 21/11 - Biblioteca El Fontán (Uviéu) /// 22/11 - Librería Gil (Santander) /// 25/11 Casa de la Cultura (Lluanco) /// 26/11 - Librería La Revoltosa (Xixón) /// 27/11 Viva Bicicletas (Madrid) /// 10/12 - Katakrak (Iruñea) Otros enlaces: https://go.ivoox.com/rf/140346204 podcast Café y Ciclismo https://cyclingreport.substack.com/ proyecto Javi Aguilar 🗣️ Con Eneko Carrillo, Gabriele Gianuzzi y Albert Rivera 📍 Encuéntranos en... ➡️ https://www.twitch.tv/acdpeloton ➡️https://youtube.es/ACDPeloton ➡️Grupo de Telegram: https://t.me/familiaACDP ➡️Twitter: twitter.com/ACDPeloton ➡️Instagram: https://www.instagram.com/acdpeloton/ Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

Os jornalistas João de Andrade Neto, Daniel Leal e Juan Torres debatem as consequências extracampo do jogo entre Sport e Flamengo, com mais torcedores do time carioca presentes na Arena de Pernambuco. O papel da direção do Sport, defesa de mercados dos clubes locais e a polêmica nas redes sociais. Programa também debateu os bastidores políticos do Leão.

Muchos más recursos para tu vida de fe (Santo Rosario, Oración, etc.) en nuestra web https://sercreyente.com________________Miércoles, 19 de noviembre de 2025 (33ª Semana del Tiempo Ordinario)Evangelio del día y reflexión... ¡Deja que la Palabra del Señor transforme tu vida! Texto íntegro del Evangelio y de la Reflexión en https://sercreyente.com/parabola-diez-minas-oro-talentos/[Lucas 19, 11-28] En aquel tiempo, añadió Jesús una parábola, porque él estaba cerca de Jerusalén y pensaban que el reino de Dios iba a manifestarse enseguida. Dijo, pues: «Un hombre noble se marchó a un país lejano para conseguirse el título de rey, y volver después. Llamó a diez siervos suyos y les repartió diez minas de oro, diciéndoles: “Negociad mientras vuelvo”. Pero sus conciudadanos lo aborrecían y enviaron tras de él una embajada diciendo: “No queremos que este llegue a reinar sobre nosotros”. Cuando regresó de conseguir el título real, mandó llamar a su presencia a los siervos a quienes había dado el dinero, para enterarse de lo que había ganado cada uno. El primero se presentó y dijo: “Señor, tu mina ha producido diez”. Él le dijo: “Muy bien, siervo bueno; ya que has sido fiel en lo pequeño, recibe el gobierno de diez ciudades”. El segundo llegó y dijo: “Tu mina, señor, ha rendido cinco”. A ese le dijo también: “Pues toma tú el mando de cinco ciudades”. El otro llegó y dijo: “Señor, aquí está tu mina; la he tenido guardada en un pañuelo, porque tenía miedo, pues eres un hombre exigente que retiras lo que no has depositado y siegas lo que no has sembrado”. Él le dijo: “Por tu boca te juzgo, siervo malo. ¿Conque sabías que soy exigente, que retiro lo que no he depositado y siego lo que no he sembrado? Pues ¿por qué no pusiste mi dinero en el banco? Al volver yo, lo habría cobrado con los intereses”. Entonces dijo a los presentes: “Quitadle a este la mina y dádsela al que tiene diez minas”. Le dijeron: “Señor, ya tiene diez minas”. “Os digo: al que tiene se le dará, pero al que no tiene se le quitará hasta lo que tiene. Y en cuanto a esos enemigos míos, que no querían que llegase a reinar sobre ellos, traedlos acá y degolladlos en mi presencia”». Dicho esto, caminaba delante de ellos, subiendo hacia Jerusalén.________________Descárgate la app de SerCreyente en https://sercreyente.com/app/¿Conoces nuestra Oración Online? Más información en: https://sercreyente.com/oracion¿Quieres recibir cada día el Evangelio en tu whatsapp? Alta en: www.sercreyente.com/whatsappTambién puedes hacer tu donativo en https://sercreyente.com/ayudanos/Contacto: info@sercreyente.com

In today's episode, we break down everything from Democrats fumbling their Epstein email “reveal,” to MTG taking aim at Trump, to Michelle Obama igniting fresh controversy with her comments on America and beauty standards.Scott Jennings joins the conversation multiple times to unpack the political fallout, from Epstein connections to MTG's feud with Trump, to Van Jones discussing Israel.We also cover new reporting on Eric Swalwell, SNAP re-application rules, RFK Jr.'s family blasting him, the Possum Lady attacking Riley Gaines and Karoline Leavitt, Tucker Carlson losing sponsors, and a whole lot more.SUPPORT OUR SPONSORS TO SUPPORT OUR SHOW!Try OneSkin's OS-01 topical supplements, including OS-01 Eye and OS-01 Face, at 15% off with code CHICKS at https://OneSkin.co/Chicks—support our show by telling them we sent you!Step into the holiday season with timeless, feel-good style from Quince—visit https://Quince.com/ChicksFree for free shipping, 365-day returns, and effortless gifting. Now available in Canada. Protect your family from cybercrime with 60% off Webroot Total Protection at https://Webroot.com/Chicks for this limited-time offer!Get a full-size $39 bottle of Fresh-Pressed Olive Oil for just $1 shipping at https://ChicksLoveOliveOil.com — no commitment!Get 38% off your Angel Guild membership and stream uplifting entertainment this Christmas at https://Angel.com/Chicks

NEW! Support your strength and muscle goals with PUORI Creatine+ — a clean, effective creatine monohydrate supplement enhanced with taurine. Get 20% off at puori.com/VANESSA In today's episode, we take a powerful deep dive into women's metabolism during perimenopause and midlife with Dr. Hannah Cabré, postdoctoral fellow at Pennington Biomedical Research Center and 2025 Fellow of the Year. We break down why body composition changes so dramatically for women in their late 30s, 40s, and 50s — and what the latest science says you can do to stay strong, lean, and metabolically healthy through this transition. Dr. Cabré explains what's actually driving muscle loss, increased protein turnover, shifts in fat distribution, and changes in fuel use, and she shares evidence-based nutrition and training strategies that truly move the needle. OneSkin is powered by the breakthrough peptide OS-01, the first ingredient proven to reduce skin's biological age. I use the OS-01 Face and Eye formulas daily—they've transformed my skin's smoothness, firmness, and glow. Visit oneskin.co/VANESSA and use code VANESSA for 15% off your first purchasee In this episode, we cover: What perimenopause is and why symptoms vary so much How estrogen loss increases protein turnover and belly fat Aging vs. menopause: what's hormonal and what's not Protein needs for women (1.2–1.6 g/kg) and how to hit them Simple meal-by-meal protein goals for muscle retention The best diet pattern for postmenopausal women Mediterranean-style eating, nitrates, and vascular health Olive oil, fish, omega-3s & lowering inflammation Creatine for women: strength, mood, cognition & hydration Key micronutrients for each stage of a woman's life Cycle syncing vs. what the science actually shows Sleep, hydration & recovery strategies to reduce fatigue Nutrition approaches that support fat loss & body recomposition If you're navigating perimenopause, noticing body composition changes, or simply want to understand how to fuel and train smarter in your 30s, 40s, and 50s, this episode will give you clarity, confidence, and science-based tools you can use today. NEW! Free High-Protein Keto Guide  Get delicious high protein meal recipes! Connect with Vanessa on Instagram @ketogenicgirl Get 20% off on the Tone Device breath ketone analyzer or the Tone LUX Crystal Red Light Therapy Mask or the at https://ketogenicgirl.com with the code VANESSA Follow @optimalproteinpodcast on Instagram to see visuals and posts mentioned on this podcast. Link to join the Facebook group for the podcast The content provided in this podcast is for informational purposes only and should not be construed as medical advice. Consult with a healthcare professional before making significant changes to your diet or exercise regimen.

Durante este programa da Escola do Amor Responde, Renato Cardoso compartilhou um trecho de uma palestra recente que ele e a esposa, Cristiane Cardoso, ministraram no Templo de Salomão, em São Paulo. Na oportunidade, o casal blindado deu continuidade ao tema “como cortar as raízes ruins” na sua vida. Acompanhe na íntegra no Univer Vídeo.Quer a família de voltaEm seguida, Robson pediu ajuda. Ele contou que ama a esposa, que se entregou demais e que investiu nela. Contudo, teve uma grande decepção, que doeu muito. Ela o traiu com um homem que trabalhou com eles há muito tempo. Os dois estão há 17 anos juntos e ele acredita que ela o trai desde quando ele a conheceu. Robson disse que parece loucura, mas não é. O aluno disse que é triste não conhecer a pessoa a fundo antes de se unir a ela.Ele contou que a mãe dela é da igreja e ela também era. Ademais, a esposa de Robson já teve um casamento que chegou ao fim por causa de uma traição do ex-marido. No início era tudo muito legal e ela, inclusive, era muito “safada” com ele, mas, segundo Robson, ele não acreditava que isso poderia ser um problema no futuro. Ele não sabe se ela quis dar o troco no primeiro “bobo” que apareceu.Ademais, o aluno comentou outras questões, inclusive que a companheira é muito narcisista, não fala a verdade e nega, colocando o nome de Deus nas conversas. Ele não acredita na mudança dela e disse que gostaria de ter a família de volta.Bem-vindos à Escola do Amor Responde, confrontando os mitos e a desinformação nos relacionamentos. Onde casais e solteiros aprendem o Amor Inteligente. Renato e Cristiane Cardoso, apresentadores da Escola do Amor, na Record TV, e autores de Casamento Blindado e Namoro Blindado, tiram dúvidas e respondem perguntas dos alunos. Participe pelo site EscoladoAmorResponde.com. Ouça todos os podcasts no iTunes: rna.to/EdARiTunes

Un capítulo especial para descubrir la belleza de la mujer, la verdadera belleza que Dios ha entregado a cada una de ellas. Dios está comprometido con la belleza real. Él no hace apaños. Al Lío! . Aquí el forms para los Ejercicios Espirituales de diciembre https://forms.gle/SEPLcNhKcdhyyBqz8 . Sobre la Consagración para Mujeres que no pueden tener hijos: La Virgen puso un deseo en nuestro corazón: que todas aquellas mujeres que tienen el anhelo de ser madres y han encontrado alguna dificultad en el camino, le encomienden su vientre a la Virgen María. Ella tiene sed de vosotras, quiere mostraros que no estáis solas, que vuestro matrimonio y vuestras vidas ya son fecundos. Comenzaremos la novena el *25 de noviembre con una adoración en la parroquia de San Clemente Romano, en Madrid a las 20:30h.* Os esperamos a a vosotras y a vuestros maridos, no dudéis en venir, aunque sea solas, el señor quiere mostrarse presente en tu realidad, en vuestra realidad. *La novena terminará el día 03 de diciembre con una alabanza en la parroquia San Clemente Romano a las 20:30h* https://chat.whatsapp.com/E6dqpZvCN8i6OgOEIto5Nt?mode=wwt . Por cierto, me tienes en Instagram https://instagram.com/joaquinconp?igshid=YmMyMTA2M2Y= . Y la edición me la hace el gran Edu, de Archi, cuya paciencia es infinita https://archidigitalgroup.com . Sé feliz! +

Neste episódio, Ricardo fala sobre a nova edição do PMBOK 8, que traz mudanças importantes e mais alinhadas ao trabalho real dos gerentes de projetos. Baseada em quase 48 mil dados e duas rodadas de feedback global, ela se tornou mais prática, clara e orientada a valor. Os antigos 12 princípios foram condensados em seis mais focados, mantendo o bom comportamento em projetos. Os tradicionais cinco grupos de processos retornam e passam a valer para projetos preditivos, ágeis e híbridos. As antigas áreas de conhecimento evoluíram para sete domínios de desempenho: governança, escopo, cronograma, finanças, stakeholders, recursos e riscos. A edição também traz 40 processos atualizados com ITTOs integrados e reforça o tailoring com exemplos práticos, tornando o guia mais aplicável e equilibrado. Escute o podcast para saber mais.

No “Estadão Analisa” desta segunda-feira, 17, Carlos Andreazza comenta sobre as possíveis candidaturass bolsonaristas para enfrentar o PT em 2026, o senador Flávio Bolsonaro (PL-RJ) publicou uma foto com o governador de São Paulo, Tarcísio de Freitas (Republicanos), para defender união da direita. Os dois são cotados para herdar o lugar do ex-presidente Jair Bolsonaro (PL), que está condenado a 27 anos de prisão por tentativa de golpe de Estado e prestes a seguir para a prisão. Eleito ao Senado em 2018, Flávio precisará defender sua candidatura em 2026 se quiser continuar no Senado. Caso concorra à Presidência da República e perca, ficará sem mandato. Assine por R$1,90/mês e tenha acesso ilimitado ao conteúdo do Estadão.Acesse: https://bit.ly/oferta-estadao O 'Estadão Analisa' é transmitido ao vivo de segunda a sexta-feira, às 7h, no Youtube e redes sociais do Estadão. Também disponível no agregador de podcasts de sua preferência. Apresentação: Carlos AndreazzaEdição/Produção: Jefferson PerlebergCoordenação: Leonardo Cruz e Everton OliveiraSee omnystudio.com/listener for privacy information.

Neste vlog especial do Podcast Imigrante Rico Educação, Chay Dias mostra os bastidores do BR Nation, evento que reúne grandes nomes do empreendedorismo e gestão, como André Dueck, Sandro Ribeiro (presidente da Havaianas América do Norte) e José Salibi Neto, autor do best-seller Gestão do Amanhã.Entre voos, credenciamento e entrevistas exclusivas, esse episódio mostra o lado real da expansão, da liderança e da conexão entre brasileiros que estão transformando o cenário empresarial nos Estados Unidos.

Podcast Mayhem 039 - Com Rodrigo Ramos - O que são Florais? Para que servem? https://projetomayhem.com.br/ O vídeo desta conversa está disponível em: https://youtu.be/8mZ7TyUL3fQ Bate Papo Mayhem é um projeto extra desbloqueado nas Metas do Projeto Mayhem.  Todas as 3as, 5as e Sabados as 21h os coordenadores do Projeto Mayhem batem papo com algum convidado sobre Temas escolhidos pelos membros, que participam ao vivo da conversa, podendo fazer perguntas e colocações. Os vídeos ficam disponíveis para os membros e são liberados para o público em geral duas vezes por semana, às segundas e quintas feiras e os áudios são editados na forma de podcast e liberados uma vez por semana. Faça parte do projeto Mayhem: https://www.catarse.me/tdc

Os moradores do Bairro Alto, em Lisboa, criaram uma associação para combater aquilo a que chamam “Disneylândia do álcool”.

A vida da Jéssica nunca foi fácil, aos 4 anos sua mãe a doou para uma conhecida. Aos 15, ela se envolveu com o William, um homem mais velho, que prometeu esperá-la até completar os 18 anos. Eles se casaram, mas tudo se tornou um pesadelo marcado por drogas, agressões e medo. Após 12 anos de sofrimento, ela teve coragem de se separar com o apoio da mãe. Mais tarde, Jéssica conheceu o Adriano, um homem carinhoso e temente a Deus, que a levou de volta à igreja e a fez reencontrar a fé. Mais tarde, ela ficou grávida, mas com 24 semanas, teve pré-eclâmpsia e síndrome HELLP. Os médicos precisaram salvar a mãe, e o pequeno Adryan viveu apenas por 40 minutos. A dor foi indescritível, mas o Adriano cuidou dela com amor. A Jéssica sobreviveu por um milagre e hoje acredita que Deus lhe deu uma nova chance. O Adryan sempre será sua estrelinha no céu e tudo que acontece, é para nos ensinar.

Confira nesta edição do JR 24 Horas: Trinta pessoas foram presas em flagrante em uma operação da Polícia Civil do Rio de Janeiro contra receptadores de celulares roubados. A investigação começou em maio, com a prisão de um homem responsável por desbloquear celulares roubados. Na ação desta segunda-feira (17), cerca de 2,5 mil aparelhos foram recuperados. Além do Rio de Janeiro, a operação aconteceu em outros dez estados. Os investigados são suspeitos de revender os celulares roubados e também de acessar os dados das vítimas, como aplicativos de bancos. R$ 52 mil foram apreendidos. E ainda: Polícia prende suspeitos de planejar atentados contra autoridades no Rio Grande do Sul.

Atenção (disclaimer): Os dados aqui apresentados representam minha opinião pessoal.Não são de forma alguma indicações de compra ou venda de ativos no mercado financeiro.Julia Ioffe Wants You to Know Russia Is Bigger Than Putinhttps://podcasts.apple.com/br/podcast/julia-ioffe-wants-you-to-know-russia-is-bigger-than-putin/id1845840408?i=1000735675638&l=en-GBTarcísio reativa articulações para se tornar aposta da direita para 2026https://podcasts.apple.com/br/podcast/tarc%C3%ADsio-reativa-articula%C3%A7%C3%B5es-para-se-tornar-aposta/id203963267?i=1000736091670&l=en-GB‘We needed to change the equation,' Sen. Kaine says on his vote to end shutdownhttps://podcasts.apple.com/br/podcast/we-needed-to-change-the-equation-sen-kaine-says-on/id78304589?i=1000736181362&l=en-GBTrump pardons dozens of allies who tried to overturn his 2020 election loss to Bidenhttps://podcasts.apple.com/br/podcast/trump-pardons-dozens-of-allies-who-tried-to-overturn/id78304589?i=1000736180087&l=en-GBCasamento infantil: a violência que ninguém vêhttps://podcasts.apple.com/br/podcast/casamento-infantil-a-viol%C3%AAncia-que-ningu%C3%A9m-v%C3%AA/id1477406521?i=1000736201990&l=en-GBAl-Sharaa meets with Trump at White House as Syria seeks closer ties with the Westhttps://podcasts.apple.com/br/podcast/al-sharaa-meets-with-trump-at-white-house-as-syria/id78304589?i=1000736180399&l=en-GBWhy a K-Shaped US Economy Is Raising Red Flagshttps://podcasts.apple.com/br/podcast/why-a-k-shaped-us-economy-is-raising-red-flags/id1578096201?i=1000736171958&l=en-GBPfizer and Novo Nordisk's $10bn battle over weight-loss drugshttps://podcasts.apple.com/br/podcast/pfizer-and-novo-nordisks-%2410bn-battle-over-weight/id1376303362?i=1000736372684&l=en-GBDesaprovação do governo Lula aumenta e aprovação cai após megaoperação no Rio, diz Quaesthttps://podcasts.apple.com/br/podcast/desaprova%C3%A7%C3%A3o-do-governo-lula-aumenta-e-aprova%C3%A7%C3%A3o-cai/id203963267?i=1000736405972&l=en-GBMegaoperação no Rio interrompe recuperação da popularidade de Lulahttps://podcasts.apple.com/br/podcast/megaopera%C3%A7%C3%A3o-no-rio-interrompe-recupera%C3%A7%C3%A3o-da-popularidade/id203963267?i=1000736413330&l=en-GBRODA VIVA | VICTOR DOS SANTOS | 10/11/2025https://podcasts.apple.com/br/podcast/roda-viva-victor-dos-santos-10-11-2025/id1483511325?i=1000736301338&l=en-GBMP-RJ informa STF que vai usar tecnologia 3D para analisar mortes na megaoperaçãohttps://podcasts.apple.com/br/podcast/mp-rj-informa-stf-que-vai-usar-tecnologia-3d-para-analisar/id1588271061?i=1000736508077&l=en-GBTrump faces fresh Epstein questions as new emails and files are releasedhttps://podcasts.apple.com/br/podcast/trump-faces-fresh-epstein-questions-as-new-emails-and/id78304589?i=1000736510656&l=en-GBChildren wounded by the war in Gaza share their stories as they heal in the U.S.https://podcasts.apple.com/br/podcast/children-wounded-by-the-war-in-gaza-share-their/id78304589?i=1000736510645&l=en-GBU.S. carrier in Caribbean amid Venezuela tensions and outcry over drug boat strikeshttps://podcasts.apple.com/br/podcast/u-s-carrier-in-caribbean-amid-venezuela-tensions-and/id78304589?i=1000736515095&l=en-GBTrump Promised Revenge. He's Using the DOJ to Make It Happenhttps://podcasts.apple.com/br/podcast/trump-promised-revenge-hes-using-the-doj-to-make-it-happen/id1578096201?i=1000736502131&l=en-GBQuaest: Lula mantém liderança na disputa presidencial, mas volta a ter empate técnico com Bolsonarohttps://podcasts.apple.com/br/podcast/quaest-lula-mant%C3%A9m-lideran%C3%A7a-na-disputa-presidencial/id203963267?i=1000736571627&l=en-GB‘He Knew': What Epstein Said About Trump in New Emailshttps://podcasts.apple.com/br/podcast/he-knew-what-epstein-said-about-trump-in-new-emails/id1200361736?i=1000736573426&l=en-GBUOL Prime #96:https://podcasts.apple.com/br/podcast/uol-prime-96-o-neg%C3%B3cio-da-china-feito-pelo-governador/id1574996957?i=1000736555344&l=en-GB

Os debates com os candidatos presidenciais, nos canais generalistas (SIC, RTP e TVI), arrancam hoje e vão prolongar-se até ao dia 22 de dezembro. Os candidatos vão estar frente-a-frente com todos os adversários, aproximadamente 30 minutos em horário nobre (21h00). Quem tem mais a ganhar e quem tem mais a perder? Como vai ser percorrido um caminho que se prevê ir acabar numa segunda volta? Procuramos respostas numa conversa com o subdiretor de informação da SIC, Martim Silva.See omnystudio.com/listener for privacy information.

No podcast ‘Notícia No Seu Tempo’, confira em áudio as principais notícias da edição impressa do jornal ‘O Estado de S.Paulo’ desta segunda-feira (17/11/2025): Em ano de eleição, os partidos entrarão em 2026 com pelo menos R$ 6,4 bilhões em caixa, volume recorde desde 2017, maior do que o orçamento somado de oito ministérios do governo federal e o valor de mercado de 27 companhias listadas na Bolsa de Valores brasileira. Os recursos disponíveis para as legendas são públicos e vêm do Fundo Partidário e do Fundo Especial de Financiamento de Campanha, conhecido como fundo eleitoral. A verba é ainda incrementada por rendimentos de aplicações financeiras que as siglas fazem antes de começar a distribuir o dinheiro entre os candidatos. Especialistas dizem que o modelo concentra poder nos dirigentes, o que torna a gestão partidária pouco transparente. Para eles, o sistema acentua desigualdade entre as siglas, reduz o controle sobre o gasto do dinheiro público e limita tanto a competitividade eleitoral quanto a renovação interna das legendas. E mais: Economia: Em 5 anos, Pix muda a forma como o consumidor paga suas compras Política: Emissora de rádio que faz oposição a Alcolumbre tem licença cancelada Metrópole: Saúde diz que vai agir contra médicos que faturam com ‘spikeopatia’ Internacional: Candidatos comunista e da ultradireita vão ao 2º turno no Chile Esportes: Rayssa Leal confirma domínio e é penta do STU Pro Tour RioSee omnystudio.com/listener for privacy information.

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! En esta tercera hora de DÍAS EXTRAÑOS exploramos los límites de lo creíble. Comenzamos con una reflexión sobre nuestra capacidad única como especie para crear realidades mediante la creencia, y cómo eso nos convierte en seres extraordinarios... y peligrosos. Luego viajamos a 1968, al altiplano boliviano, donde Valentina Flores se enfrentó cara a cara con algo que no era de este mundo: seres extraños mutilando su ganado con precisión quirúrgica. Después nos sumergimos en el fascinante mundo del espionaje real: las herramientas, trucos y técnicas que los agentes de la CIA y el KGB usaban de verdad, desde monedas huecas hasta cámaras del tamaño de un reloj. Continuamos con el Ningen, la criatura humanoide gigante y blanca que supuestamente acecha las aguas antárticas. Y cerramos con una de las historias más escalofriantes que he contado jamás: el "Safari de Sarajevo", donde ricos europeos pagaban hasta 100.000 euros por cazar civiles durante el asedio de la ciudad. Una investigación que acaba de reabrirse en 2025 y que podría llevar a los culpables ante la justicia... treinta años después. Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

En este episodio especial grabado en directo durante el II Congreso de Misterio e Historia de Valencia, DÍAS EXTRAÑOS ofrece uno de sus programas más emotivos e intensos. Comenzamos recordando la tragedia de la DANA de 2024 con testimonios desgarradores de Maika y Carlos, supervivientes y voluntarios que vivieron el horror en primera persona. Luego, un momento de magia con Luis Antonio Muñoz y el experimento del piano que nos conecta con la belleza de lo efímero. Josep Guijarro nos adentra en el fascinante mundo de los no identificados, desde las revelaciones de David Grush hasta los misterios de Montserrat. Y cerramos con Manuel Martín Loeches explorando los mayores enigmas: nuestro propio cerebro, las emociones y la consciencia. Un programa que mezcla lágrimas, asombro y conocimiento a partes iguales. Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

Hellooooooo :) Hoy nos ponemos en marcha otra vez, un poco de orden en la vida !!! Os dejo links por aquí: MI JOURNAL (el más sencillo del mundo): https://amzn.eu/d/4ZHe51MVideos sobre empezar y disciplina: 1. https://youtu.be/iwT59y8LWfE?si=6e2WhaBpRO2qcGWo2. https://youtu.be/gJctVD_oMx4?si=8xD1uM7Qi2OHKtrn3. https://youtu.be/PZ7lDrwYdZc?si=x1FHacepbBk8CUrGNOS VEMOS EN INSTAGRAM Y TIKTOK @LAIASCASTEL

Os tempos duros não te quebram, te moldam.Joel mostra que o que hoje dói, amanhã fortalece, e que fugir das fases difíceis é o mesmo que abrir mão da sua própria evolução.

LAUDES SÁBADO DE LA XXXII SEMANA DEL TIEMPO ORDINARIO(Oración de la mañana) - IV Salterio*Link de apoyo al canal al final del escrito*INVOCACIÓN INICIALV. Señor abre mis labiosR. Y mi boca proclamará tu alabanzaINVITATORIOAnt. Escuchemos la voz del Señor y entremos en su descanso.SALMODIASalmo 91 - Ant.Es bueno tocar para tu nombre, oh Altísimo, y proclamar por la mañana tu misericordia.Cántico - Ant. Os daré un corazón nuevo y os infundiré un espíritu nuevo.Salmo 8 - Ant. De la boca de los niños de pecho, Señor, has sacado una alabanzaCÁNTICO EVANGÉLICOAnt. Guía nuestros pasos, Dios de Israel, por el camino de la paz.Cántico de Zacarías. EL MESÍAS Y SU PRECURSOR      Lc 1, 68-79Bendito sea el Señor, Dios de Israel,porque ha visitado y redimido a su pueblo.suscitándonos una fuerza de salvaciónen la casa de David, su siervo,según lo había predicho desde antiguopor boca de sus santos profetas:Es la salvación que nos libra de nuestros enemigosy de la mano de todos los que nos odian;ha realizado así la misericordia que tuvo con nuestros padres,recordando su santa alianzay el juramento que juró a nuestro padre Abraham.Para concedernos que, libres de temor,arrancados de la mano de los enemigos,le sirvamos con santidad y justicia,en su presencia, todos nuestros días.Y a ti, niño, te llamarán Profeta del Altísimo,porque irás delante del Señora preparar sus caminos,anunciando a su pueblo la salvación,el perdón de sus pecados.Por la entrañable misericordia de nuestro Dios,nos visitará el sol que nace de lo alto,para iluminar a los que viven en tinieblay en sombra de muerte,para guiar nuestros pasospor el camino de la paz.Gloria al Padre, y al Hijo, y al Espíritu Santo.Como era en el principio, ahora y siempre, por los siglos de los siglos. Amén.PRECES“Escúchanos, Señor. ”ConclusionV. El Señor nos bendiga, nos guarde de todo mal y nos lleve a la vida eterna.R. Amén.(658)

Hur tränar en av Sveriges bästa långdistanslöpare – och vad kan du som motionär lära dig utan att gå sönder? I det här avsnittet berättar OS-tolvan Sarah Lahti om resan från skolmilen till världsscenen, varför styrketräningen blev hennes stora vändpunkt och hur hon använder tröskelpass, backar och smart återhämtning för att utvecklas. Vi pratar om skadorna som nästan stoppade allt, hur hon mentalt tar sig tillbaka och varför elitlöpare ofta är mer avslappnade kring mat än många motionärer. Dessutom får du en inblick i livet på träningsläger, hur hon tänker kring spikskor vs kolfiberskor – och vad hon drömmer om framåt. Massvis med inspiration och tips till löpare på alla nivåer. Tack för att du lyssnar!Följ Spring med Petra & CO i sociala medier:Instagram: https://www.instagram.com/springmedpetraFacebook: https://www.facebook.com/springmedpetraFölj Petra:Instagram: https://www.instagram.com/maratonpetra Hosted on Acast. See acast.com/privacy for more information.

Join Jim and Greg for the Friday 3 Martini Lunch as they dig into President Trump reducing several key tariffs, Megyn Kelly's confounding comments about Jeffrey Epstein, and Sen. John Fetterman how criticism he gets from the left is far worse than what he hears from the right. First, they welcome President Trump's decision to lower tariffs on coffee, bananas, and other major imports from four Latin American nations. Jim sees this as a quiet admission that tariffs have been driving up prices. They also hope this signals a broader push to ease the cost of living in this country. Next, parents may want the kids out of the room for this segment. Jim and Greg react to Megyn Kelly saying a source close to the Jeffrey Epstein case believes Epstein was not technically a pedophile because he preferred "barely legal" girls around fifteen years old instead of pre-pubescent victims. Jim and Greg are horrified by multiple aspects of her statement and discuss the Trump administration's terrible handling of this issue.Finally, they highlight Pennsylvania Sen. John Fetterman saying there is no comparison between the vitriol he receives from the right and the left. Fetterman says angry Republicans call him names, while the left openly wishes for his death. We are not the same. Please visit our great sponsors:OneSkin uses the patented OS-01 Peptide™ designed to keep skin healthier, stronger, and more resilient over time. Get 15% off OneSkin with the code 3ML at https://www.OneSkin.co/3ML Try the Oracle Cloud Infrastructure for free with zero commitment by visiting https://Oracle.com/Martini today!Open a new qualified IRA or cash account with Noble Gold and get a free 10-ounce Silver Flag Bar plus a Silver American Eagle Proof Coin—visit https://NobleGoldInvestments.com/3ML

Jacob Ward of The Rip Current joins Mikah Sargent this week! Tech titans are investing millions into genetically engineered babies. A lot of those who worry about data privacy feel like their actions make no difference. Comments from Windows lead Pavan Davuluri on the future of Windows received a lot of blowback online. And Valve announced a trio of new hardware for. Jacob discusses tech billionaires funding companies that are pursuing genetically engineered babies, raising concerns about the commercialization of polygenic screening. Mikah talks about how a lot of Americans do worry about data privacy, but feel helpless in that any actions they may take make no real difference. Zac Bowden from Windows Central joins the show to talk about comments made recently online from Windows lead Pavan Davuluri on the future of Windows "evolving into an agentic OS," which received plenty of pushback. And Scott Stein of CNET stops by to share his hands-on experience with Valve's recently announced new Steam hardware, set to launch in 2026. Hosts: Mikah Sargent and Jacob Ward Guests: Zac Bowden and Scott Stein Download or subscribe to Tech News Weekly at https://twit.tv/shows/tech-news-weekly. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit Sponsors: pantheon.io veeam.com threatlocker.com/twit cachefly.com/twit

Jacob Ward of The Rip Current joins Mikah Sargent this week! Tech titans are investing millions into genetically engineered babies. A lot of those who worry about data privacy feel like their actions make no difference. Comments from Windows lead Pavan Davuluri on the future of Windows received a lot of blowback online. And Valve announced a trio of new hardware for. Jacob discusses tech billionaires funding companies that are pursuing genetically engineered babies, raising concerns about the commercialization of polygenic screening. Mikah talks about how a lot of Americans do worry about data privacy, but feel helpless in that any actions they may take make no real difference. Zac Bowden from Windows Central joins the show to talk about comments made recently online from Windows lead Pavan Davuluri on the future of Windows "evolving into an agentic OS," which received plenty of pushback. And Scott Stein of CNET stops by to share his hands-on experience with Valve's recently announced new Steam hardware, set to launch in 2026. Hosts: Mikah Sargent and Jacob Ward Guests: Zac Bowden and Scott Stein Download or subscribe to Tech News Weekly at https://twit.tv/shows/tech-news-weekly. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit Sponsors: pantheon.io veeam.com threatlocker.com/twit cachefly.com/twit

Jacob Ward of The Rip Current joins Mikah Sargent this week! Tech titans are investing millions into genetically engineered babies. A lot of those who worry about data privacy feel like their actions make no difference. Comments from Windows lead Pavan Davuluri on the future of Windows received a lot of blowback online. And Valve announced a trio of new hardware for. Jacob discusses tech billionaires funding companies that are pursuing genetically engineered babies, raising concerns about the commercialization of polygenic screening. Mikah talks about how a lot of Americans do worry about data privacy, but feel helpless in that any actions they may take make no real difference. Zac Bowden from Windows Central joins the show to talk about comments made recently online from Windows lead Pavan Davuluri on the future of Windows "evolving into an agentic OS," which received plenty of pushback. And Scott Stein of CNET stops by to share his hands-on experience with Valve's recently announced new Steam hardware, set to launch in 2026. Hosts: Mikah Sargent and Jacob Ward Guests: Zac Bowden and Scott Stein Download or subscribe to Tech News Weekly at https://twit.tv/shows/tech-news-weekly. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit Sponsors: pantheon.io veeam.com threatlocker.com/twit cachefly.com/twit

It's a wet November evening across Western Europe, the steel-grey clouds have obscured a rare low-latitude aurora this week, and Elliot Williams is joined by Jenny List for this week's podcast. And we've got a fine selection for your listening pleasure! The 2025 Component Abuse Challenge has come to an end, so this week you'll be hearing about a few of the entries. We've received an impressive number, and as always we're bowled over by the ingenuity of Hackaday readers in pushing parts beyond their limits. In the news is the potential discovery of a lost UNIX version in a dusty store room at the University of Utah, Version 4 of the OS, which appeared in 1973. Check out your own stores, for hidden nuggets of gold. In the hacks, we have two cameras at the opposite end of the resolution spectrum, but sharing some impressive reverse engineering. Mouse cameras and scanner cameras were both a thing a couple of decades ago, and it's great to see people still pushing the boundaries. Then we look at the challenge of encoding Chinese text as Morse code, an online-upgraded multimeter, the art of making lenses for an LED lighting effect, and what must be the best recreation of a Star Wars light sabre we have ever seen. In quick hacks we have a bevvy of Component Abuse Challenge projects, a Minecraft server on a smart light bulb, and a long term test of smartphone battery charging techniques. We round off with a couple of our long-form pieces, first the uncertainties about iRobot's future and what it might mean for their ecosystem -- think: cheap hackable robotics platform! -- and then a look at FreeBSD as an alternative upgrade path for Windows users. It's a path not without challenges, but the venerable OS still has plenty to give. As always, check out the links to all the articles over on Hackaday.

Jacob Ward of The Rip Current joins Mikah Sargent this week! Tech titans are investing millions into genetically engineered babies. A lot of those who worry about data privacy feel like their actions make no difference. Comments from Windows lead Pavan Davuluri on the future of Windows received a lot of blowback online. And Valve announced a trio of new hardware for. Jacob discusses tech billionaires funding companies that are pursuing genetically engineered babies, raising concerns about the commercialization of polygenic screening. Mikah talks about how a lot of Americans do worry about data privacy, but feel helpless in that any actions they may take make no real difference. Zac Bowden from Windows Central joins the show to talk about comments made recently online from Windows lead Pavan Davuluri on the future of Windows "evolving into an agentic OS," which received plenty of pushback. And Scott Stein of CNET stops by to share his hands-on experience with Valve's recently announced new Steam hardware, set to launch in 2026. Hosts: Mikah Sargent and Jacob Ward Guests: Zac Bowden and Scott Stein Download or subscribe to Tech News Weekly at https://twit.tv/shows/tech-news-weekly. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit Sponsors: pantheon.io veeam.com threatlocker.com/twit cachefly.com/twit

Join Jim and Greg for the Thursday 3 Martini Lunch as they celebrate the end of a pointless government shutdown, blast United Nations Secretary-General Antonio Guterres for trying to silence free speech online, and recoil at how shockingly bad college students have become at math.First, Jim and Greg applaud the House vote to end the government shutdown, rip Democrats for their six weeks of incoherent grandstanding, and look ahead to late January when this may happen all over again.Next, they unload on Secretary-General Guterres for claiming online “disinformation and misinformation” are poisoning discourse and insisting that tech companies have a responsibility to crack down on speech that supposedly distorts the facts. Guterres says this speech he doesn't like is hampering the UN's ability to enact its climate agenda. Well, that's a shame. Jim not only defends free speech but points out that the UN should not be involved in this debate at all.Finally, they shudder as college professors warn that incoming students are much worse at math than ever before. One study finds fewer than 20 percent can handle middle school–level math, and many struggle with even the most basic concepts. Jim and Greg consider how so many young adults made it to college so poorly prepared.Please visit our great sponsors:Get 10% off your first month of BetterHelp by visiting https://BetterHelp.com/3ML today!OneSkin uses the patented OS-01 Peptide™ designed to keep skin healthier, stronger, and more resilient over time. Get 15% off OneSkin with the code 3ML at https://www.OneSkin.co/3ML Try the Oracle Cloud Infrastructure for free with zero commitment by visiting https://Oracle.com/Martini today!